1. Lugari R，Dell'Anna C，Ugolotti D，et al. Effect of nutrient ingestion on glucagon-like peptide 1 （7-36 amide） secretion in human type 1 and type 2 diabetes. Horm Metab Res，2000，32（10）：424-428.

2. Toft-Nielsen MB，Damholt MB，Madsbad S，et al.Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab，2001，86：3717-3723.

3. Nauck MA，Kleine N，Orskov C，et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 （7-36 amide） in type 2 （non-insulin-dependent） diabetic patients. Diabetologia，1993，36：741-744.

4. Meier JJ，Nauck MA. Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus？ Nat Clin Pract Endocrinol Metab，2008，4：606-607.

5. Vollmer K，Holst JJ，Baller B，et al. Predictors of incretin concentrations in subjects with normal，impaired，and diabetic glucose tolerance. Diabetes，2008，57（3）：678-687.

6. Knop FK，Vilsbøll T，Højberg PV，et al. Reduced incretin effect in type 2 diabetes：cause or consequence of the diabetic state？ Diabetes，2007，56（8）：1951-1919.

7. Nauck MA，Bartels E，Orskov C，et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-（7-36） amide infused at nearphysiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab，1993，76（4）：912-917.

8. Holst JJ，Gromada J，Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia，1997，40（8）：984-986.

9. Xu G，Kaneto H，Laybutt DR，et al.Downregulation of GLP-1 and GIP receptor expression by hyperglycemia：possible contribution to impaired incretin effects in diabetes.Diabetes，2007，56 （6）：1551-1558.

10. Meier JJ，Gallwitz B，Kask B，et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes，2004，53（Suppl 3）：S220- S224.

11. Lynn FC，Pamir N，Ng EH，et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes，2001，50（5）：1004-1011.

12. Nauck MA，El-Ouaghlidi A，Gabrys B，et al. Secretion of incretin hormones （GIP and GLP-1）and incretion effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept，2004，122（3）：209-217.

13. Kubota A，Yamada Y，Hayami T，Y et al. Identification of two missense mutations in the GIP receptor gene：a functional study and association analysis with NIDDM：no evidence of association with Japanese NIDDM subjects. Diabetes，1996，45（12）：1701-1705.

14. Saxena R，Hivert MF，Langenberg C，et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet，2010，42：142-148.

15. Shu L，Matveyenko AV，Kerr-Conte J，et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP-and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet，2009，18（13）：2388-2399.

16. Iwasa M，Yamada Y，Kobayashi H，et al. Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemiareperfusion injury in rabbits.Br J Pharmacol，2011，164（1）：119-131.

17. Hattori A，Kawamura I，Yamada Y，et al. Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction：a cross-sectional study.BMJ Open，2013，3（9）：e003201.

18. During MJ，Cao L，Zuzga DS，et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med，2003，9（9）：1173-1179.

19. Hamilton A，Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport，2009，20（13）：1161-1166.

20. Perry T，Holloway HW，Weerasuriya A，et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol，2007，203 （2）：293-301.

21. Iwai T，Ito S，Tanimitsu K，Udagawa S，et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res，2006 Aug，55（4）：352-360.

22. Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm，2010，84：331-354.

23. Hölscher C，Li L. New roles for insulin-like hormones in neuronal signalling and protection：new hopes for novel treatments of Alzheimer's disease？ Neurobiol Aging，2010，31（9）：1495-1502.

24. Iwai T，Ito S，Tanimitsu K，et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res，2006，55（4）：352-360.

25. Gengler S，McClean PL，McCurtin R，et al. Val（8）GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging，2012，33：265-276.

26. Wang XH，Li L，Hölscher C，et al. Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience，2010，170 （4）：1239-1248.

27. Perry T，Lahiri DK，Sambamurti K，et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide （Abeta） levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res，2003，72 （5）：603-612.

28. Hamilton A，Patterson S，Porter D，et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res，2011，89 （4）：481-489.

29. Hölscher C. Central effects of GLP-1：new opportunities for treatments of neurodegenerative diseases. J Endocrinol，2014，221（1）：T31-41.

30. Bertilsson G，Patrone C，Zachrisson O，et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res，2008，86（2）：326-338.

31. Aviles-Olmos I，Dickson J，Kefalopoulou Z，et al. Exenatide and the treatment of patients with Parkinson's disease.J Clin Invest，2013，123（6）：2730-2736.

32. Li Y，Chigurupati S，Holloway HW，et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One，2012，7（2）：e32008.

33. Knippenberg S，Thau N，Dengler R，et al. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One，2012，7（6）：e36857.

34. Holst JJ，Burcelin R，Nathanson E. Neuroprotective properties of GLP-1：theoretical and practical applications. Curr Med Res Opin，2011，27（3）：547-558.

35. Lee CH，Yan B，Yoo KY，et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist，exendin-4，in experimental transient cerebral ischemia. J Neurosci Res，2011，89（7）：1103-1113.

36. Teramoto S，Miyamoto N，Yatomi K，et al. Exendin-4，a glucagon-like peptide-1 receptor agonist，provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab，2011，31（8）：1696-1705.

37. Himeno T，Kamiya H，Naruse K，et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes，2011，60（9）：2397-2406.

38. Ligumsky H，Wolf I，Israeli S，et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat，2012，132（2）：449-461.

39. Miyawaki K，Yamada Y，Ban N，et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity.Nat Med，2002，8（7）：738-742.

40. Zhou H，Yamada Y，Tsukiyama K，et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action.Biochem Biophys Res Commun，2005，335 （3）：937-942.

41. Naitoh R，Miyawaki K，Harada N，et al. Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice.Biochem Biophys Res Commun，20087，376（1）：21-25.

42. McClean PL，Irwin N，Cassidy RS，et al. GIP receptor antagonism reverses obesity，insulin resistance，and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab，2007，293（6）：E1746-55.

43. Korner J，Bessler M，Inabnet W，et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis，2007，3：597-601.

44. N'Diaye N，Tremblay J，Hamet P，et al. Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome. J Clin Endocrinol Metab，1998，83（8）：2781-2785.

45. Umahara M，Okada S，Ohshima K，et al. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocr J，2003，50（5）：643-650.